GlaxoSmithKline, in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), has announced the start of a global phase III study that will examine the role of lapatinib in the treatment of early breast cancer (EBC).
The details can be read here.
No comments:
Post a Comment